CymaBay Therapeutics, Inc. (NASDAQ: CBAY) saw its shares inch up Wednesday, as the clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will host a virtual analyst day on seladelpar, the company’s lead asset in development for patients with the autoimmune liver disease, primary biliary cholangitis (PBC) on Thursday, September 22.
The Analyst Day will feature a presentation from a hepatology key opinion leader, Kris Kowdley, Director of Liver Institute Northwest and Professor of Medicine at Washington State University, who will discuss the current treatment landscape and future goals for treating patients with PBC.
CymaBay’s seladelpar is a potent, selective, orally active delpar or PPARd agonist, in late-stage development for patients with PBC. Members of CymaBay’s leadership team will discuss updates on the seladelpar clinical development program, recently presented data, and potential patient impact in the U.S. and globally.
CBAY shares gained six cents, or 1.5%, to $3.80.
